Physician profile
Mark E Reynolds
NPI 1992857437
$16,258.86
in general payments reported to CMS, 2019-2025
21 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,461 · 2020: $101 · 2021: $6,971 · 2022: $351 · 2023: $65.90 · 2024: $185 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $374.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $12,685.41 | 2019-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $2,209.46 | 2019-2025 | Abilify Maintena, Abilify Asimtufii |
| Ironshore Pharmaceuticals INC. | $306.99 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $129.34 | 2020-2022 | |
| Corium, LLC | $121.83 | 2024 | Azstarys |
| Lundbeck LLC | $84.07 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $80.41 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.53 | 2019-2021 | |
| Johnson & Johnson Health Care Systems INC. | $74.71 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $73.24 | 2022 | |
| Vanda Pharmaceuticals INC. | $66.68 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $65.90 | 2023 | Quviviq |
| Neurocrine Biosciences, INC. | $57.67 | 2024-2025 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $55.40 | 2019 | |
| Allergan, INC. | $55.09 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $24.87 | 2019 | |
| Noven Therapeutics, LLC | $21.68 | 2025 | Xelstrym |
| Jazz Pharmaceuticals INC. | $20.24 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.04 | 2022 | |
| Supernus Pharmaceuticals, INC. | $15.38 | 2021 | |
| Bausch Health US, LLC | $13.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Reynolds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.